FIELD: medicine, particularly, neurology and neurogenetics. SUBSTANCE: semax is introduced intranasally in day dose of 9-90 mcg/kg of patient weight with interval of 4-5 h. EFFECT: higher efficiency of treatment in restoration of intellectual-mnestic functions of human nervous system and improved state of patient.
Title | Year | Author | Number |
---|---|---|---|
NOOTROPIC DRUG AND PHARMACEUTICAL NOOTROPIC COMPOSITION | 1994 |
|
RU2045958C1 |
METHOD FOR TREATMENT OF NERVOUS SYSTEM DISORDER IN CHILDREN OF YOUNGEST AGE AND PHARMACEUTICAL COMPOSITION | 2003 |
|
RU2241487C1 |
METHOD FOR TREATING THE CASES OF ISCHEMIC INSULT | 1997 |
|
RU2124365C1 |
MEANS AND DEVICE FOR TREATING THE CASES OF OPTIC NERVE NEURITIS HAVING INFLAMMATORY, TOXICOALLERGIC OR VASCULAR ETIOLOGY AND OPTIC NERVE ATROPHY | 1999 |
|
RU2157258C1 |
METHOD OF TREATING DISEASES OF SUBCORTICAL NERVOUS SYSTEM | 2000 |
|
RU2168997C1 |
AGENT FOR TREATMENT OF LATE DEGENERATIVE DISEASE OF NERVOUS SYSTEM | 0 |
|
SU1819151A3 |
ANXIOLYTIC AGENT AND PHARMACEUTICAL COMPOSITION WITH ANXIOLYTIC EFFECT | 1999 |
|
RU2155065C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING ISCHEMIC INSULT AND METHOD FOR THERAPY | 2002 |
|
RU2251429C2 |
NOOTROPIC ANTIALCOHOLIC DRUG | 1985 |
|
RU2020937C1 |
METHOD OF PRODUCING INDUCED PLURIPOTENT STEM CELLS FROM FIBROBLASTS OF PATIENTS WITH HUNTINGTON'S DISEASE | 2011 |
|
RU2458983C1 |
Authors
Dates
1999-09-10—Published
1996-04-10—Filed